KBC Group NV Cuts Stock Position in Edwards Lifesciences Corporation $EW

KBC Group NV reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 22.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 371,758 shares of the medical research company’s stock after selling 107,030 shares during the quarter. KBC Group NV’s holdings in Edwards Lifesciences were worth $31,692,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Viking Global Investors LP purchased a new stake in Edwards Lifesciences during the 3rd quarter valued at about $238,688,000. Jennison Associates LLC boosted its holdings in Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after acquiring an additional 2,287,783 shares during the period. Bank of New York Mellon Corp boosted its holdings in Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after acquiring an additional 1,423,365 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Edwards Lifesciences by 114.5% during the 3rd quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock valued at $161,055,000 after acquiring an additional 1,111,139 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the sale, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 86,058 shares of company stock worth $7,118,636. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.9%

NYSE EW opened at $78.90 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $68.63 and a fifty-two week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The stock has a 50 day simple moving average of $81.23 and a two-hundred day simple moving average of $82.03. The stock has a market cap of $45.49 billion, a P/E ratio of 43.11, a price-to-earnings-growth ratio of 2.04 and a beta of 0.95.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter last year, the business posted $0.59 EPS. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on EW. Evercore reiterated an “outperform” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 5th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research report on Wednesday, April 1st. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $90.00 to $100.00 in a research report on Thursday, December 18th. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Finally, Robert W. Baird set a $90.00 price objective on Edwards Lifesciences in a research report on Monday, January 12th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $95.74.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.